“…The new sequences were designed by reducing the peptide length [magainin 2(1-10)], replacing the Trp residues by D-Phe (BP525), incorporating an acyl group (BP526 to BP529), preparing the amidated C-terminal analogs (RR2-NH 2 , RR3-NH 2 , and RR4-NH 2 ), replacing D-amino acids by their L-enantiomers (RJK2), or replacing a Lys by an Arg (AamAP-R). These modifications have been reported to increase the antimicrobial activity of peptides (Guell et al, 2011;Cutrona et al, 2015;Vasilchenko et al, 2017;Oliveras et al, 2021).…”